TargetBeta
OPRK1
opioid receptor kappa 1 · also KOR, OPRK · Opioid receptors
8 programs in company-led studies act on OPRK1, from 8 companies: 4 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (7 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Naltrexonerule | Orexigen Therapeutics | antagonist | phase 4 | 425 running | OPRD1, OPRM1 | ChEMBL |
| Nalbuphinerule | Trevi Therapeutics | agonist | phase 4 | 214 running | OPRD1, OPRM1 | ChEMBL |
| nalmefenerule | H. Lundbeck | – | phase 4 | 201 running | OPRD1, OPRM1 | ChEMBL |
| cebranopadolrule | Tris Pharma | agonist | phase 3 | 182 running | OPRD1, OPRL1, OPRM1, PNOC | ChEMBL |
| Aticaprantrule | Johnson & Johnson | antagonist | phase 3 | 131 running | – | ChEMBL |
| nalfurafinerule | Toray Industries | agonist | phase 3 | 91 running | – | ChEMBL |
| asimadolinerule | Tioga Pharmaceuticals | agonist | phase 3 | 61 running | – | ChEMBL |
| icalcaprant | AbbVie | antagonist | phase 2 | 62 running | – | the company's pipeline |
Conditions their studies are in
- Pruritus, 4 programs
- Alcoholism, 3 programs
- Depressive Disorder, Major, 2 programs
- Opioid-Related Disorders, 2 programs
- Acute Pain, 1 program
- Bipolar Disorder, 1 program
- Chronic Cough, 1 program
- Chronic Pain, 1 program
- Depression, 1 program
- Diarrhea, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 30, 2026Nalbuphine · Trevi Therapeutics · phase 4 · NCT07946575
- Jan 2027cebranopadol · Tris Pharma · phase 3 · NCT07845071
- Mar 1, 2027nalmefene · H. Lundbeck · phase 4 · NCT06733519
- Apr 1, 2027Naltrexone · Orexigen Therapeutics · phase 4 · NCT07433413
- Jun 21, 2027Aticaprant · Johnson & Johnson · phase 3 · NCT07615426
- Sep 2027icalcaprant · AbbVie · phase 2 · NCT07276997
- Oct 31, 2027asimadoline · Tioga Pharmaceuticals · phase 3 · NCT07042516
- Dec 30, 2027nalfurafine · Toray Industries · phase 3 · NCT07905976
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.